Takeda Pharmaceutical Co LTD (TAK)
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Last price
- $20.15
- As of
Kresmion compiles this page from TAK's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
TAKEDA PHARMACEUTICAL CO LTD (TAK): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-09-14.
See the full TAK dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for TAK on one page. Preview it with sample data, then open it live with a free account.
Preview the TAK dossierActive events for TAK
- high13F: large reduction
CITADEL ADVISORS LLC cut 52% of TAK (2026Q2)
- high13F: large reduction
CITADEL ADVISORS LLC cut 89% of TAK (2026Q2)
- high13F: funds added
3 tracked funds increased TAK this 2026Q2, institutional consensus
- medium13F: new position
Point72 Asset Management, L.P. new position in TAK
- high13F: large increase
MILLENNIUM MANAGEMENT LLC added +179% to TAK (2026Q2)
FREE, NO ACCOUNT
Every event on TAK, as it fires
You are seeing 5 of 13 events recorded on TAK since 2026-06-05.
The five above all landed on 2026-08-16. The other 8 were recorded on 4 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in TAK (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 874060205 · 2026Q2 | $41.2M | 0.06% | , |
| D. E. Shaw & Co., Inc.CUSIP 874060205 · 2026Q2 | $32.9M | 0.02% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 874060205 · 2026Q2 | $16.8M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 874060205 · 2026Q2 | $7.8M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 874060205 · 2026Q2 | $2.7M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 874060205 · 2026Q2 | $1.2M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, TAK
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
TAK against its peers
TAK's operating margin of 7.5% ranks in the 48th percentile of 19 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2024-12-31 and 2025-12-31.
| Metric | TAK | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 4.6T JPY | n/a | n/a | 0 |
| Revenue YoY | 7.5% | 2.0% | 56 | 7 |
| Gross margin | 65.5% | 55.4% | 79 | 20 |
| Operating margin | 7.5% | 11.2% | 48 | 19 |
| Net margin | 2.4% | -3.4% | 55 | 20 |
| Return on equity | 1.6% | -3.5% | 58 | 17 |
Peers (21): HLN, RDY, ELAN, KNSA, INDV, RGC, HCM, PBH, CURLF, PRGO, TRLV, ALVO, ETON, GTBIF, CRON, HROW, EVO, AQST, EOLS, KMDA, VREOF. Left out: GALDY (no annual filing), JHPCY (no annual filing), SGIOF (no annual filing), HYPMY (no annual filing). Fiscal periods ending between 2024-12-31 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (TAK: 20-F), reported in JPY. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow TAK on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to TAK for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.